ACTRN12618000288224
已完成
1 期
A Phase 2 placebo controlled, double-blind randomised clinical trial assessing the efficacy of a Herbal supplement for Nocturnal Enuresis in Children
Endeavour College of Natural Health0 个研究点目标入组 42 人2018年2月23日
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- octurnal enuresis in children
- 发起方
- Endeavour College of Natural Health
- 入组人数
- 42
- 状态
- 已完成
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Any gender
- •Has bed wetting issues equal to or greater than 3 times per week (wet nights)
- •Aged: equal to or greater than 6 years old to equal to or less than 14 years old
排除标准
- •Vesicoureteral reflux
- •Spinal dysraphism
- •Recent urotherapy
- •Recent or current urinary tract infection (\< 1 week)
- •Active cancer currently on treatment
- •History of cardiac failure
- •History of renal dysfunction or urinary retention
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC-0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effectiveAdvanced or metastatic breast cancer resistant to aromatase inhibitor therapyMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023763-17-DKGenentech, Inc.260
进行中（未招募）
1 期
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC-0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effectiveAdvanced or metastatic breast cancer resistant to aromatase inhibitor therapyMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023763-17-DEGenentech, Inc.260
进行中（未招募）
1 期
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC-0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effectiveAdvanced or metastatic breast cancer resistant to aromatase inhibitor therapyMedDRA version: 14.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023763-17-HUGenentech, Inc.350
进行中（未招募）
1 期
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC-0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effectiveAdvanced or metastatic breast cancer resistant to aromatase inhibitor therapyMedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023763-17-BEGenentech, Inc.260
进行中（未招募）
不适用
Study of the novel cancer drug GDC-0941 in combination with the approved anticancer drug fulvestrant, and the novel cancer drug GDC- 0980 in combination with fulvestrant, in patients with advanced breast cancer for whom treatment with an aromatase inhibitor is not effectiveAdvanced or metastatic breast cancer resistant to aromatase inhibitortherapy.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-023763-17-ITROCHE350